분화성 갑상선암과 관련된 유전자의 메틸화

키워드

참고문헌 (86)

1. Feinberg AP, "The history of cancer epigenetics", Nat Rev Cancer, 4(2), pp.143~153 (2004)
2. Herman JG, "Gene silencing in cancer in association with promoter hypermethylation", N Engl J Med, 349(21), pp.2042~2054 (2003)
3. Waddington CH, "The epigenotype. 1942", Int J Epidemiol, 41(1), pp.10~13 (2012)
4. Feinberg AP, "Hypomethylation distinguishes genes of some human cancers from their normal counterparts", Nature, 301(5895), pp.89~92 (1983)
5. Greger V, "Epigenetic changes may contribute to the formation and spontaneous regression of retinoblastoma", Hum Genet, 83(2), pp.155~158 (1989)
6. Xing M, "Gene methylation in thyroid tumorigenesis", Endocrinology, 148(3), pp.948~953 (2007)
7. Bird A, "DNA methylation patterns and epigenetic memory", Genes Dev, 16(1), pp.6~21 (2002)
8. Yoo CB, "Epigenetic therapy of cancer: past, present and future", Nat Rev Drug Discov, 5(1), pp.37~50 (2006)
9. Yokomori N, "Regulation of the rat thyrotropin receptor gene by the methylation-sensitive transcription factor GA-binding protein", Mol Endocrinol, 12(8), pp.1241~1249 (1998)
10. Reik W, "Co-evolution of X-chromosome inactivation and imprinting in mammals", Nat Rev Genet, 6(5), pp.403~410 (2005)
11. Feinberg AP, "DNA methylation and genomic imprinting: insights from cancer into epigenetic mechanisms", Semin Cancer Biol, 12(5), pp.389~398 (2002)
12. Feinberg AP, "The epigenetic progenitor origin of human cancer", Nat Rev Genet, 7(1), pp.21~33 (2006)
13. Robertson KD, "DNA methylation and chromatin - unraveling the tangled web", Oncogene, 21(35), pp.5361~5367 (2002)
14. Kornberg RD, "Twenty-five years of the nucleosome, fundamental particle of the eukaryote chromosome", Cell, 98(3), pp.285~294 (1999)
15. 박일석, "두경부 암 영역에서의 Epigenetics", 대한이비인후과학회지 두경부외과학, 52(12), pp.943~948 (2009), 대한이비인후과학회
16. Piperi C, "Strategies for DNA methylation analysis in developmental studies", Dev Growth Differ, 53(3), pp.287~299 (2011)
17. He L, "MicroRNAs: small RNAs with a big role in gene regulation", Nat Rev Genet, 5(7), pp.522~531 (2004)
18. "Cancer", 1998, 2638~2648
19. Hu S, "Association of aberrant methylation of tumor suppressor genes with tumor aggressiveness and BRAF mutation in papillary thyroid cancer", Int J Cancer, 119(10), pp.2322~2329 (2006)
20. 고희자, "DNA Methylation of RUNX3 in Papillary Thyroid Cancer", The Korean Journal of Internal Medicine, 27(4), pp.407~410 (2012), 대한내과학회[DOI]
21. Mohammadi-asl J, "Qualitative and quantitative promoter hypermethylation patterns of the P16, TSHR, RASSF1A and RARbeta2 genes in papillary thyroid carcinoma", Med Oncol, 28(4), pp.1123~1128 (2011)
22. Porra V, "Silencing of the tumor suppressor gene SLC5A8 is associated with BRAF mutations in classical papillary thyroid carcinomas", J Clin Endocrinol Metab, 90(5), pp.3028~3035 (2005)
23. Wang P, "Methylation of p16 CpG islands correlated with metastasis and aggressiveness in papillary thyroid carcinoma", J Chin Med Assoc, 76(3), pp.135~139 (2013)
24. Anania MC, "TIMP3 regulates migration, invasion and in vivo tumorigenicity of thyroid tumor cells", Oncogene, 30(27), pp.3011~3023 (2011)
25. Anand-Apte B, "A review of tissue inhibitor of metalloproteinases-3(TIMP-3) and experimental analysis of its effect on primary tumor growth", Biochem Cell Biol, 74(6), pp.853~862 (1996)
26. Gomez DE, "Tissue inhibitors of metalloproteinases: structure, regulation and biological functions", Eur J Cell Biol, 74(2), pp.111~122 (1997)
27. Qi JH, "A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2", Nat Med, 9(4), pp.407~415 (2003)
28. Guan Z, "Promoter methylation and expression of TIMP3 gene in gastric cancer", Diagn Pathol, 8, pp.110~ (2013)
29. Catasus L, "Promoter hypermethylation contributes to TIMP3 down-regulation in high stage endometrioid endometrial carcinomas", Histopathology, 62(4), pp.632~641 (2013)
30. Sun W, "Detection of TIMP3 promoter hypermethylation in salivary rinse as an independent predictor of local recurrence-free survival in head and neck cancer", Clin Cancer Res, 18(4), pp.1082~1091 (2012)
31. Brait M, "Correlation between BRAF mutation and promoter methylation of TIMP3, RARbeta2 and RASSF1A in thyroid cancer", Epigenetics, 7(7), pp.710~719 (2012)
32. Miyauchi S, "Functional identification of SLC5A8, a tumor suppressor down-regulated in colon cancer, as a Na(+)-coupled transporter for short-chain fatty acids", J Biol Chem, 279(14), pp.13293~13296 (2004)
33. Li H, "SLC5A8, a sodium transporter, is a tumor suppressor gene silenced by methylation in human colon aberrant crypt foci and cancers", Proc Natl Acad Sci U S A, 100(14), pp.8412~8417 (2003)
34. Elangovan S, "Molecular mechanism of SLC5A8inactivation in breast cancer", Mol Cell Biol, 33(19), pp.3920~3935 (2013)
35. Park JY, "Gene silencing of SLC5A8 identified by genome-wide methylation profiling in lung cancer", Lung Cancer, 79(3), pp.198~204 (2013)
36. Park JY, "Silencing of the candidate tumor suppressor gene solute carrier family 5 member 8 (SLC5A8) in human pancreatic cancer", Pancreas, 36(4), pp.e32~e39 (2008)
37. Zane M, "Circulating cell-free DNA, SLC5A8 and SLC26A4 hypermethylation, BRAF(V600E): A non-invasive tool panel for early detection of thyroid cancer", Biomed Pharmacother, 67(8), pp.723~730 (2013)
38. Lam AK, "Clinicopathological roles of alterations of tumor suppressor gene p16 in papillary thyroid carcinoma", Ann Surg Oncol, 14(5), pp.1772~1779 (2007)
39. Serrano J, "Alterations in the p16INK4a", CDKN2A tumor suppressor gene in gastrinomas, 2000, pp.85(11), 4146~4156
40. 김윤정, "갑상선 유두암에서 p16INK4A 촉진자 과메틸화와 p16INK4A, cyclin D1 및 Rb 발현", 대한내과학회지, 78(3), pp.333~340 (2010), 대한내과학회
41. Schagdarsurengin U, "Frequent epigenetic silencing of the CpG island promoter of RASSF1A in thyroid carcinoma", Cancer Res, 62(13), pp.3698~3701 (2002)
42. Soprano DR, "Retinoic acid receptors and cancers", Annu Rev Nutr, 24, pp.201~221 (2004)
43. Hoque MO, "Quantitative assessment of promoter methylation profiles in thyroid neoplasms", J Clin Endocrinol Metab, 90(7), pp.4011~4018 (2005)
44. Kiseljak-Vassiliades K, "Association of cigarette smoking with aberrant methylation of the tumor suppressor gene RARbeta2 in papillary thyroid cancer", Front Endocrinol (Lausanne), 2, pp.99~ (2011)
45. Schneider-Stock R, "DAP-kinase--protector or enemy in apoptotic cell death", Int J Biochem Cell Biol, 37(9), pp.1763~1767 (2005)
46. Nomura T, "Influence of HRH2 promoter polymorphism on aberrant DNA methylation of DAPK and CDH1 in the gastric epithelium", BMC Gastroenterol, 13, pp.1~ (2013)
47. Eisenberg-Lerner A, "DAPk silencing by DNA methylation conveys resistance to anti EGFR drugs in lung cancer cells", Cell Cycle, 11(11), pp.2051~ (2012)
48. Xiaofang L, "Correlation between promoter methylation of p14(ARF), TMS1", ASC, and DAPK, and p53 mutation with prognosis in cholangiocarcinoma, 2012, pp.10, 5~
49. Coffman JA, "Runx transcription factors and the developmental balance between cell proliferation and differentiation", Cell Biol Int, 27(4), pp.315~324 (2003)
50. Blyth K, "The RUNX genes: gain or loss of function in cancer", Nat Rev Cancer, 5(5), pp.376~387 (2005)
51. De Falco V, "RET", papillary thyroid carcinoma oncogenic signaling through the Rap1 small GTPase, 2007, pp.67(1), 381~390
52. Wang Z, "Rap1-mediated activation of extracellular signal-regulated kinases by cyclic AMP is dependent on the mode of Rap1activation", Mol Cell Biol, 26(6), pp.2130~2145 (2006)
53. Zhang L, "Identification of a putative tumor suppressor gene Rap1GAP in pancreatic cancer", Cancer Res, 66(2), pp.898~906 (2006)
54. Tsygankova OM, "Downregulation of Rap1GAP contributes to Ras transformation", Mol Cell Biol, 27(19), pp.6647~6658 (2007)
55. Zuo H, "Downregulation of Rap1GAP through epigenetic silencing and loss of heterozygosity promotes invasion and progression of thyroid tumors", Cancer Res, 70(4), pp.1389~1397 (2010)
56. Kondo T, "Pathogenetic mechanisms in thyroid follicular-cell neoplasia", Nat Rev Cancer, 6(4), pp.292~306 (2006)
57. Xing M, "BRAF mutation in thyroid cancer", Endocr Relat Cancer, 12(2), pp.245~262 (2005)
58. Groussin L, "Significance of BRAF mutations in papillary thyroid carcinoma: prognostic and therapeutic implications", Nat Clin Pract Endocrinol Metab, 2(4), pp.180~181 (2006)
59. Lupi C, "Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma", J Clin Endocrinol Metab, 92(11), pp.4085~4090 (2007)
60. Xing M, "BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer", J Clin Endocrinol Metab, 90(12), pp.6373~6379 (2005)
61. Li X, "BRAF mutation in papillary thyroid carcinoma", Int J Clin Exp Med, 5(4), pp.310~315 (2012)
62. Kim TH, "The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis", Cancer, 118(7), pp.1764~1773 (2012)
63. Santoro A, "BRAF mutation and RASSF1A expression in thyroid carcinoma of southern Italy", J Cell Biochem, 114(5), pp.1174~1182 (2013)
64. Xing M, "Early occurrence of RASSF1A hypermethylation and its mutual exclusion with BRAF mutation in thyroid tumorigenesis", Cancer Res, 64(5), pp.1664~1668 (2004)
65. de Vogel S, "MGMT and MLH1promoter methylation versus APC, KRAS and BRAF gene mutations in colorectal cancer: indications for distinct pathways and sequence of events", Ann Oncol, 20(7), pp.1216~1222 (2009)
66. Guan H, "Hypermethylation of the DNA mismatch repair gene hMLH1and its association with lymph node metastasis and T1799A BRAF mutation in patients with papillary thyroid cancer", Cancer, 113(2), pp.247~255 (2008)
67. Santos JC, "Correlation of MLH1 and MGMT expression and promoter methylation with genomic instability in patients with thyroid carcinoma", BMC Cancer, 13, pp.79~ (2013)
68. Jo YS, "Influence of the BRAF V600E mutation on expression of vascular endothelial growth factor in papillary thyroid cancer", J Clin Endocrinol Metab, 91(9), pp.3667~3670 (2006)
69. Fresno Vara JA, "PI3K", Akt signalling pathway and cancer, 2004, pp.30(2), 193~204
70. Alvarez-Nunez F, "PTEN promoter methylation in sporadic thyroid carcinomas", Thyroid, 16(1), pp.17~23 (2006)
71. Hou P, "Association of PTEN gene methylation with genetic alterations in the phosphatidylinositol 3-kinase", AKT signaling pathway in thyroid tumors, 2008, pp.113(9), 2440~2447
72. Donninger H, "The RASSF1A tumor suppressor", J Cell Sci, 120(Pt 18), pp.3163~3172 (2007)
73. Agathanggelou A, "Role of the Ras-association domain family 1 tumor suppressor gene in human cancers", Cancer Res, 65(9), pp.3497~3508 (2005)
74. Nilsson M, "Iodide handling by the thyroid epithelial cell", Exp Clin Endocrinol Diabetes, 109(1), pp.13~17 (2001)
75. Caillou B, "Na+", I- symporter distribution in human thyroid tissues: an immunohistochemical study, 1998, pp.83(11), 4102~4106
76. Sherman SI, "Thyroid carcinoma", Lancet, 361(9356), pp.501~511 (2003)
77. Smith JA, "Methylation status of genes in papillary thyroid carcinoma", Arch Otolaryngol Head Neck Surg, 133(10), pp.1006~1011 (2007)
78. Galrao AL, "Methylation levels of sodium-iodide symporter (NIS) promoter in benign and malignant thyroid tumors with reduced NIS expression", Endocrine, 43(1), pp.225~229 (2013)
79. Stephen JK, "DNA methylation in thyroid tumorigenesis", Cancers (Basel), 3(2), pp.1732~1743 (2011)
80. Kopp P, "The TSH receptor and its role in thyroid disease", Cell Mol Life Sci, 58(9), pp.1301~1322 (2001)
81. Xing M, "Methylation of the thyroid-stimulating hormone receptor gene in epithelial thyroid tumors: a marker of malignancy and a cause of gene silencing", Cancer Res, 63(9), pp.2316~2321 (2003)
82. Everett LA, "Pendred syndrome is caused by mutations in a putative sulphate transporter gene (PDS)", Nat Genet, 17(4), pp.411~422 (1997)
83. Xing M, "Hypermethylation of the Pendred syndrome gene SLC26A4 is an early event in thyroid tumorigenesis", Cancer Res, 63(9), pp.2312~2315 (2003)
84. Xu XC, "Differential expression of galectin-1 and galectin-3 in thyroid tumors. Potential diagnostic implications", Am J Pathol, 147(3), pp.815~822 (1995)
85. Keller S, "DNA methylation state of the galectin-3gene represents a potential new marker of thyroid malignancy", Oncol Lett, 6(1), pp.86~90 (2013)
86. Sassa M, "Aberrant promoter methylation in overexpression of CITED1 in papillary thyroid cancer", Thyroid, 21(5), pp.511~517 (2011)

관련 논문AI추천